Intellia Therapeutics (NTLA) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 0.81.
- Intellia Therapeutics' Equity Ratio fell 140.59% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year decrease of 140.59%. This contributed to the annual value of 0.73 for FY2024, which is 930.41% down from last year.
- Per Intellia Therapeutics' latest filing, its Equity Ratio stood at 0.81 for Q3 2025, which was down 140.59% from 0.8 recorded in Q2 2025.
- Intellia Therapeutics' Equity Ratio's 5-year high stood at 0.84 during Q1 2023, with a 5-year trough of 0.73 in Q4 2024.
- Moreover, its 5-year median value for Equity Ratio was 0.81 (2023), whereas its average is 0.8.
- As far as peak fluctuations go, Intellia Therapeutics' Equity Ratio soared by 1537.07% in 2021, and later tumbled by 930.41% in 2024.
- Over the past 5 years, Intellia Therapeutics' Equity Ratio (Quarter) stood at 0.8 in 2021, then rose by 1.15% to 0.81 in 2022, then fell by 0.69% to 0.81 in 2023, then decreased by 9.3% to 0.73 in 2024, then increased by 10.48% to 0.81 in 2025.
- Its Equity Ratio stands at 0.81 for Q3 2025, versus 0.8 for Q2 2025 and 0.79 for Q1 2025.